FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2323173645> ?p ?o ?g. }

• W2323173645 abstract "Objective: To characterize patients with neurological autoimmune disorders (NADs) who have been treated with the therapeutic monoclonal antibody rituximab in our center. Background Rituximab depletes peripheral CD20-bearing B cells. Clinical efficacy in relapsing-remitting multiple sclerosis (MS) was shown in a phase II trial. Treatment benefits for neuromyelitis optica (NMO), inflammatory neuropathies (IN) and myasthenia gravis (MG) can be deduced from published open label case series. Design/Methods: Databases of patient records and pharmacy prescriptions at Heinrich-Heine university medical center were queried to identify patients with NADs who received at least one treatment with rituximab. Patient records were reviewed for epidemiological and disease related parameters. Results: Since 2004 61 patients (mean age 46 ±16 years; 67 % females) have been treated with a median of 1600 mg of rituximab applied in a median of 3 cycles. A total of 258 cycles were administered, resulting in 146 patient-years of follow-up. The majority of patients (n=35) had a diagnosis of MS, 6 patients suffered from NMO-spectrum disorders, 3 patients from MG, 13 from IN, and 4 cases suffered from other NADs. Rituximab treatment was initiated after a median interval of 11 years (range 1 month – 30 years) of making the respective diagnosis. Prior to rituximab patients had received a median of 6 (range 0-7) different immunomodulatory and/or –suppressive medications. In 76 % of patients rituximab was considered initially effective as judged by the treating physicians based on clinical and/or paraclinical parameters. Efficacy was least noted in patients with IN (50 %) and progressive MS without relapses (62 %). Adverse events occurred in 20 % of patients, most frequently in patients with IN (31 %). Conclusions: This open-label retrospective case series study provides evidence that rituximab treatment may be effective in selected patients with NADs even if initiated late in the disease course or if standard therapies have failed. Disclosure: Dr. Menge has received personal compensation for activities with Biogen Idec, Bayer HealthCare and Serono as a speaker. Dr. Meyer Zur Hoerste has received personal compensation for activities with Bayer Schering and Merck Serono. Dr. Meyer Zur Hoerste has received personal compensation in an editorial capacity from Remedica Education and Publishing. Dr. Meyer Zur Hoerste has received research support from the Firtz-Thyssen Foundation and the Peripheral Nerve Society. Dr. Jander has nothing to disclose. Dr. Ringelstein has nothing to disclose. Dr. Aktas has received personal compensation for activities with the German Research Council (DFG SFB-TRR43) and Bayer HealthCare, BiogenIdec, Merck-Sorono, Novartis, and Teva/Sanofi-Aventis. Dr. Kieseier has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Novartis, Roche Diagnostics, Sanofi-Aventis Pharmaceuticals, and TEVA Neurosciences as speaker. Dr. Kieseier has received research support from Bayer Pharmaceuticals, Biogen Idec, Merck Serono and Teva Neurosciences. Dr. Hartung has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, BioMS, Genzyme Corporation, Merck Serono, Novartis, Sanofi-Aventis and Teva as a speaker and/or consultant." @default.
• W2323173645 created "2016-06-24" @default.
• W2323173645 creator A5031075667 @default.
• W2323173645 creator A5037084636 @default.
• W2323173645 creator A5046354840 @default.
• W2323173645 creator A5074759103 @default.
• W2323173645 creator A5076180609 @default.
• W2323173645 creator A5082233226 @default.
• W2323173645 creator A5091555486 @default.
• W2323173645 date "2012-04-22" @default.
• W2323173645 modified "2023-09-26" @default.
• W2323173645 title "Treatment of Neurological Autoimmune Disorders with Rituximab - A 7 Years Single Center Experience (P04.140)" @default.
• W2323173645 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.140" @default.
• W2323173645 hasPublicationYear "2012" @default.
• W2323173645 type Work @default.
• W2323173645 sameAs 2323173645 @default.
• W2323173645 citedByCount "0" @default.
• W2323173645 crossrefType "journal-article" @default.
• W2323173645 hasAuthorship W2323173645A5031075667 @default.
• W2323173645 hasAuthorship W2323173645A5037084636 @default.
• W2323173645 hasAuthorship W2323173645A5046354840 @default.
• W2323173645 hasAuthorship W2323173645A5074759103 @default.
• W2323173645 hasAuthorship W2323173645A5076180609 @default.
• W2323173645 hasAuthorship W2323173645A5082233226 @default.
• W2323173645 hasAuthorship W2323173645A5091555486 @default.
• W2323173645 hasConcept C126322002 @default.
• W2323173645 hasConcept C141071460 @default.
• W2323173645 hasConcept C187212893 @default.
• W2323173645 hasConcept C203014093 @default.
• W2323173645 hasConcept C2778105408 @default.
• W2323173645 hasConcept C2779338263 @default.
• W2323173645 hasConcept C2780073493 @default.
• W2323173645 hasConcept C2780640218 @default.
• W2323173645 hasConcept C2780653079 @default.
• W2323173645 hasConcept C2781137167 @default.
• W2323173645 hasConcept C71924100 @default.
• W2323173645 hasConceptScore W2323173645C126322002 @default.
• W2323173645 hasConceptScore W2323173645C141071460 @default.
• W2323173645 hasConceptScore W2323173645C187212893 @default.
• W2323173645 hasConceptScore W2323173645C203014093 @default.
• W2323173645 hasConceptScore W2323173645C2778105408 @default.
• W2323173645 hasConceptScore W2323173645C2779338263 @default.
• W2323173645 hasConceptScore W2323173645C2780073493 @default.
• W2323173645 hasConceptScore W2323173645C2780640218 @default.
• W2323173645 hasConceptScore W2323173645C2780653079 @default.
• W2323173645 hasConceptScore W2323173645C2781137167 @default.
• W2323173645 hasConceptScore W2323173645C71924100 @default.
• W2323173645 hasLocation W23231736451 @default.
• W2323173645 hasOpenAccess W2323173645 @default.
• W2323173645 hasPrimaryLocation W23231736451 @default.
• W2323173645 hasRelatedWork W2172569637 @default.
• W2323173645 hasRelatedWork W2303917887 @default.
• W2323173645 hasRelatedWork W2334891793 @default.
• W2323173645 hasRelatedWork W2340003990 @default.
• W2323173645 hasRelatedWork W2520638610 @default.
• W2323173645 hasRelatedWork W2556353245 @default.
• W2323173645 hasRelatedWork W2561704003 @default.
• W2323173645 hasRelatedWork W2605424691 @default.
• W2323173645 hasRelatedWork W2615311368 @default.
• W2323173645 hasRelatedWork W2751800220 @default.
• W2323173645 hasRelatedWork W2785750096 @default.
• W2323173645 hasRelatedWork W2788846357 @default.
• W2323173645 hasRelatedWork W2800702435 @default.
• W2323173645 hasRelatedWork W2804834873 @default.
• W2323173645 hasRelatedWork W2810371342 @default.
• W2323173645 hasRelatedWork W2898435097 @default.
• W2323173645 hasRelatedWork W2904759668 @default.
• W2323173645 hasRelatedWork W3204374402 @default.
• W2323173645 hasRelatedWork W3208490418 @default.
• W2323173645 hasRelatedWork W2146923401 @default.
• W2323173645 isParatext "false" @default.
• W2323173645 isRetracted "false" @default.
• W2323173645 magId "2323173645" @default.
• W2323173645 workType "article" @default.